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Voltage-gated sodium (NaV) channels are important targets of general anesthetics, including the intravenous anesthetic 
propofol. Electrophysiology studies on the prokaryotic NaV channel NaChBac have demonstrated that propofol promotes 
channel activation and accelerates activation-coupled inactivation, but the molecular mechanisms of these effects are 
unclear. Here, guided by computational docking and molecular dynamics simulations, we predict several propofol-binding 
sites in NaChBac. We then strategically place small fluorinated probes at these putative binding sites and experimentally 
quantify the interaction strengths with a fluorinated propofol analogue, 4-fluoropropofol. In vitro and in vivo measurements 
show that 4-fluoropropofol and propofol have similar effects on NaChBac function and nearly identical anesthetizing effects 
on tadpole mobility. Using quantitative analysis by 19F-NMR saturation transfer difference spectroscopy, we reveal strong 
intermolecular cross-relaxation rate constants between 4-fluoropropofol and four different regions of NaChBac, including 
the activation gate and selectivity filter in the pore, the voltage sensing domain, and the S4–S5 linker. Unlike volatile 
anesthetics, 4-fluoropropofol does not bind to the extracellular interface of the pore domain. Collectively, our results show 
that propofol inhibits NaChBac at multiple sites, likely with distinct modes of action. This study provides a molecular basis 
for understanding the net inhibitory action of propofol on NaV channels.
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Introduction
Excitable cells such as neurons and myocardia communicate 
with each other by alternating electrical and chemical signals. 
The electric impulses travel along the cell surface by means of 
depolarization and repolarization involving the flow of Na+ and 
K+ ions in opposite directions across the cell membrane. The volt-
age-gated sodium (NaV) channels, which typically conduct the 
Na+ current inward, are responsible for controlling the initiation 
and propagation of action potentials. NaV channels are involved 
in a variety of physiological processes, including skeletal muscle 
contraction, heart rhythm, and neurotransmission. Accordingly, 
drugs that affect NaV channel function include anticonvulsants, 
antiarrhythmics, and antiepileptics, as well as local anesthetics 
(Amarouch and Abriel, 2015; Habib et al., 2015; Lin and Baines, 
2015; Jeevaratnam et al., 2016).
Unlike local anesthetics, it has been widely believed that gen-
eral anesthetics primarily exert their action by targeting post-
synaptic ligand-gated ion channels (Eckenhoff and Johansson, 
1997; Tang and Xu, 2002; Liu et al., 2009; Chen et al., 2010; Pan et 
al., 2012; Mowrey et al., 2013; Tillman et al., 2013; Bondarenko et 
al., 2014). However, recent experimental evidence suggests that 
NaV channels also play a critical role in the disruption of synaptic 
transmission by general anesthetics. Several functional studies 
with heterologously expressed eukaryotic NaV channels (OuYang 
and Hemmings, 2007; Purtell et al., 2015) and their bacterial 
counterparts (Hemmings et al., 2005; Barber et al., 2014; Kinde 
et al., 2016; Sand et al., 2017) have demonstrated that clinically 
relevant concentrations of general anesthetics can inhibit the 
function of NaV channels. Although local anesthetics are known 
to block the NaV channel pore and stabilize the inactivated state 
(Goldschen-Ohm and Chanda, 2014), the modes of action of gen-
eral anesthetics on NaV channels remain elusive.
General anesthetics bind to their protein targets, including 
NaV channels, with relatively low affinity (high micromolar to 
low millimolar) and high exchange rates. These low-affinity 
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binding interactions are often difficult to characterize with tra-
ditional biophysical methods because of the transient nature 
of the anesthetic–target complex. The conventional association 
or disassociation constant (Ka or Kd) measures the apparent or 
time-averaged drug–protein interactions with little binding-site 
information. In contrast, saturation transfer difference (STD) 
NMR spectroscopy is particularly well suited for quantifying 
anesthetic binding to proteins as it is a ligand-based detection 
method that can be used to probe low-affinity interactions (Kd in 
the micromolar to millimolar range) via selective magnetization 
transfer from a macromolecule to a small ligand bound under fast 
chemical exchange conditions (Mayer and Meyer, 1999). The rate 
of saturation transfer depends on the mobility of the protein and 
the ligand, the lifetime of the complex, and ligand-binding ge-
ometry (Streiff et al., 2004; Angulo et al., 2010; Venkitakrishnan 
et al., 2012). Accordingly, previous studies have shown that the 
STD cross-relaxation rate constant (initial growth rate of the 
STD signal) is a measure of ligand affinity and can be used to 
determine Kd when measured across a range of ligand concen-
trations (Angulo et al., 2010; Künze et al., 2014, 2016; Zhang et 
al., 2017; Chan et al., 2018). In particular, 19F STD NMR experi-
ments are advantageous compared with standard 1H STD NMR 
because 19F-NMR background signal is absent in protein, lipids, 
and water. Thus, 19F spectra allow for not only differentiation of 
signals that are difficult to distinguish in 1H spectra (Danielson 
and Falke, 1996; Lepre et al., 2004; Wagstaff et al., 2013) but also 
identification of drug-binding site by selective 19F probe place-
ment in the protein. In addition, the gyromagnetic ratio of 19F is 
close to that of 1H (γF/γH ∼0.94) (Lepre et al., 2004); the distance 
limit of detection for 19F STD NMR measurements is similar to 
that of standard 1H STD NMR (r < 10 Å) (Jayalakshmi and Rama 
Krishna, 2002, 2004).
The bacterial sodium channel from Bacillus halodurans (Na-
ChBac) is a structural homologue of eukaryotic NaV channels 
(Ren et al., 2001) that provides a convenient model to study 
the anesthetic interactions with NaV channels because NaCh-
Bac is easily produced in large quantities and with high purity. 
Several studies have shown that NaChBac, other bacterian NaV 
channels, and eukaryotic NaV channels are dose-dependently in-
hibited by the intravenous general anesthetic propofol (Frenkel 
and Urban, 1991; Rehberg and Duch, 1999; Haeseler and Leuwer, 
2003; Ouyang et al., 2003; Haeseler et al., 2008; Stoetzer et al., 
2016; Yang et al., in this issue). Although eukaryotic and prokary-
otic NaV channels are evolutionarily distinct—with the former 
being a single amino acid chain folded into a pseudotetrameric 
channel and the latter being a homotetrameric assembly of four 
identical subunits—these channels nevertheless share many 
similar structural features. Both eukaryotic and prokaryotic NaV 
channels consist of four voltage-sensing domains (VSDs), each 
composed of S1–S4 helices, and a pore domain (PD) composed 
of S5–S6 helices and a P-loop arranged in a tetrameric ring to 
form an ion-conducting channel. A helical S4–S5 linker, situated 
at the cytoplasmic moiety of the membrane bilayer, connects 
the VSD to the PD.
In previous studies, we demonstrated that the volatile gen-
eral anesthetics isoflurane and sevoflurane dose-dependently 
inhibit NaChBac (Barber et al., 2014; Kinde et al., 2016). Using 
site-directed labeling with small fluorinated probes, we further 
quantified the specific binding of isoflurane to various regions in 
NaChBac using 19F STD NMR (Kinde et al., 2016). In the current 
study, in silico predictions of propofol-binding sites were used 
to guide similar site-directed labeling to five different regions of 
NaChBac. Unlike isoflurane, propofol does not naturally contain 
the fluorine atoms required for 19F STD NMR, so a fluorinated 
propofol analogue (4-fluoropropofol) was synthesized. In vivo 
measurements of anesthesia were conducted to ensure that the 
physiological effects of the analogue were comparable to that 
of propofol, and in vitro electrophysiology experiments were 
performed to confirm that the mutations required for site-di-
rected labeling in NaChBac did not obstruct channel gating. 
Residue-specific binding was quantified by using 19F STD NMR, 
and the results indicate that propofol binds to multiple regions 
of NaChBac, including a site in the VSD, a pocket near the S4–S5 
linker, and within the PD.
Materials and methods
Molecular modeling
No experimental structure is currently available for NaChBac. A 
structural model of NaChBac was obtained previously (Barber 
et al., 2012) based on the crystal structure of a prokaryotic NaV 
channel from Arcobacter butzleri (NavAb) in a putative closed-
pore conformation with all four VSDs partially activated (PDB 
accession no. 3RVY; Payandeh et al., 2011). Four additional struc-
tural models of NaChBac in a variety of putative functional states 
were obtained by using Modeller 9.17 (Webb and Sali, 2014a,b) 
based on experimental crystal structures of prokaryotic NaV 
channels from Magnetococcus marinus (NavMs; PDB accession 
no. 5HVX; Sula et al., 2017), Rickettsiales sp. HIMB114 (NavRh; 
PDB accession no. 4DXW; Zhang et al., 2012), and NavAb (PDB 
accession nos. 5VB2 and 5VB8; Lenaeus et al., 2017). For each 
crystal structure, 25 independent NaChBac models were gener-
ated. The structure with the lowest discrete optimized potential 
energy was selected for subsequent docking calculations.
Molecular docking
AutoDock version 4.2.6 (Morris et al., 2009) was used for all 
docking calculations. Docking grids with 0.375-Å spacing were 
generated to cover the entire transmembrane domain of each 
protein structure so that all potential binding sites were consid-
ered equally. Both propofol and 4-fluoropropofol were docked 
separately to all five NaChBac structural models as well as each 
of the original template NaV channel structures by using a La-
marckian genetic algorithm with a population size of 1,000, a 
maximum of 27,000 generations, and a maximum of 25 million 
energy evaluations. A total of 500 independent docking calcula-
tions were clustered by using an RMSD cutoff of 2 Å.
MD simulations
The final frame from previous MD simulations of NaChBac 
embedded in a fully hydrated 1-palmitoyl-2-oleoyl-sn-glyce-
ro-3-phosphocholine (POPC) lipid bilayer (Barber et al., 2012) 
was used as the initial coordinates to simulate flooding NaChBac 
with propofol. The flooding simulation was performed by using 
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NAMD2.10 (Phillips et al., 2005). The simulation system con-
tained a total of ∼122,000 atoms, including a NaChBac tetramer, 
434 lipid molecules (POPC), 25,310 water molecules, 236 ions (Cl− 
and Na+), and 145 propofol molecules. Thus, the water-to-propo-
fol ratio was 174.6, equivalent to an initial aqueous concentration 
of 0.32 M. Initially, all propofol molecules were randomly distrib-
uted in the aqueous phase, and two Na+ ions were placed in the 
channel selectivity filter, in agreement with a previous compu-
tational study of NavAb showing double occupancy of the filter 
by Na+ ions (Carnevale et al., 2011). All charged amino acids were 
fully ionized at pH 7. The system was equilibrated through three 
consecutive stages of 500 ps each, in which position restraints on 
different groups were progressively released. The CHA RMM36 
force field was used for the phospholipids and CHA RMM27 for 
the protein (Lee et al., 2016). A united-atom representation was 
adopted for the acyl chains of the POPC lipid molecules (Hénin et 
al., 2008). Propofol parameters were obtained from the literature 
(LeBard et al., 2012). Periodic boundary conditions were used, 
and the electrostatic potential was evaluated by using the particle 
mesh Ewald method. The lengths of all bonds containing hydro-
gen were constrained with the SHA KE/RAT TLE algorithm. The 
system was maintained at a temperature of 300°K and pressure 
of 1 atm by using the Langevin thermostat and barostat methods 
as implemented in NAMD2.10. The reversible reference system 
propagation algorithm (rRES PA) multiple time step method 
was used, with a high-frequency time step of 2 fs and a low-fre-
quency time step of 4 fs. A trajectory of ∼1 µs was collected for 
subsequent analysis.
Site-directed 19F labeling and NMR sample preparation
Single cysteine mutations of NaChBac were prepared by using 
the same procedures as detailed previously (Kinde et al., 2016). 
In brief, the QuickChange lightning mutagenesis kit (Agilent) 
was used to mutate the selected residue to cysteine. The mutated 
NaChBac was expressed in lysogeny broth at 18°C, purified by 
using a 5-ml Ni column, and eluted with a buffer solution con-
taining 50 mM Tris, 500 mM NaCl, 500 mM imidazole, and 0.1% 
n-dodecyl-β-D-maltoside (DDM). Site-directed 19F labeling was 
achieved by covalent attachment of 3-bromo-1,1,1-trifluoroac-
etone (BTFA) to individual cysteine residues. BTFA in 50-fold 
excess was added to purified NaChBac mutants and incubated 
at 4°C overnight. After the labeling reaction was completed, the 
19F-labeled NaChBac in the tetrameric form was purified and 
separated from the free BTFA by using size-exclusion chroma-
tography (Superdex 75 10/300 GL column; GE Healthcare). The 
protein samples were further concentrated to 100 µM for NMR 
measurements. The mutation sites can be grouped into five re-
gions (see Results): (1) the apex of the VSD, including N36C and 
V40C in the S1 helix immediately above the hydrophobic con-
striction site; (2) the hinge region of the S4–S5 linker, including 
S129C and L150C; (3) the selectivity filter region, including T189C 
at the base of the selectivity filter; (4) the pore region, including 
I223C in the middle of the central cavity and F227C at the activa-
tion gate; and (5) the extracellular interface, including S208C at 
the hinge of the P2 and S6 helices.
To measure cross-relaxation rate constants between propofol 
and the fluorinated NaChBac mutants by using 19F STD experi-
ments, we used a fluorinated propofol analogue, 4-fluoro-2,6-di-
isopropylphenol (or 4-fluoropropofol). In a typical NMR sample, 
4-fluoropropofol was titrated into the protein samples in a solu-
tion of 1–2% DDM, 50 mM Tris at pH 7.7, 100 mM NaCl, 5% D2O for 
deuterium locking, and a final concentration of ∼200 µM.
NMR data acquisition and analysis
All NMR experiments were performed on a Bruker Biospin 
Avance 600 spectrometer, equipped with a 19F cryoprobe and op-
erated at a Larmor frequency of 564.68 MHz for 19F resonance. To 
maintain protein sample stability, the NMR sample temperature 
was controlled at 10°C. The STD NMR spectra were acquired by 
collecting alternating on-resonance and off-resonance 19F spec-
tra with saturation irradiations at −83.8 and −45.00 ppm, respec-
tively. Saturation was achieved by a train of Gaussian cascade 
(Q3.1000)-shaped pulses of 3 ms and an interpulse delay of 3 ms. 
Intermolecular 19F STD build-up from the protein resonance to 
the ligand resonance was determined by using saturation times 
of 0.05, 0.2, 0.5, 1.0, 2.0, and 4.0 s in a randomized order. The in-
tensities and corresponding errors of 4-fluoropropofol 19F spec-
tra were analyzed by using MestRenova v8.1.4 and TopSpin3.5. 
The STD data were fit to the following mono-exponential func-
tion and analyzed by using Prism 6:
  STD = ST  D max (1 −  e − k sat t  ) , (1)
where
  STD %  =  
 I off −  I on  _ I off  × 100, (2)
t is saturation time, and Ion and Ioff are 4-fluoropropofol peak 
intensities with on- and off-resonance saturation of the labeled 
protein peak, respectively. STDmax is the maximum (plateaued) 
STD, and ksat is the observed saturation rate constant. The 
cross-relaxation rate constant (σ), which is a direct measure of 
ligand-protein interaction strength, can be expressed as
  σ = ST  D max ×  k sat . (3)
Electrophysiology
The procedures for preparing materials, performing electro-
physiology, and data analysis are detailed previously (Yang et 
al., 2018b). To generate NaChBac mutants, point mutations 
were introduced into the WT plasmid by using the QuickChange 
site-directed mutagenesis method (Agilent). HEK-293 cells were 
transiently transfected with cDNA by using Lipofectamine 2000 
transfection reagent (Invitrogen) and seeded onto 12-mm circu-
lar glass coverslips (Fisher Scientific) 24 h before patch-clamp 
recording. Standard protocols were followed for growth and 
maintenance of cells in culture.
Voltage-dependent activation was assessed with Na+ currents 
evoked by 700-ms depolarizing steps (from −100 to +60 mV, ΔV 
= 10 mV). The holding potential (Vhold) for NaChBac WT, V40C, 
T189C, and F227C was −120 mV; for NaChBac S129C, Vhold was 
−160 mV. Prepulse inactivation in NaChBac WT, V40C, T189C, 
and F227C was assessed with a two-pulse protocol: (1) a 2-s con-
ditioning pulse (−120 mV to −10 mV, ΔV = 10 mV), followed imme-
diately by (2) a 50-ms test pulse to +10 mV; Vhold was −120 mV. In 
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NaChBac S129C, the conditioning pulse varied from −140 to −20 
mV, ΔV = 10 mV; and Vhold was −160 mV. All electrophysiology 
data are reported as mean ± SEM from n separate experiments.
Hypnotic activity in albino Xenopus laevis tadpoles
In vivo anesthetizing effects were measured for 4-fluoropropo-
fol and propofol in albino X. laevis tadpoles (stages 45–47) as de-
scribed previously (Hall et al., 2010; Woll et al., 2015). All animal 
care and experimental procedures involving X. laevis tadpoles 
were performed according to a protocol approved by the Insti-
tutional Animal Care and Use Committee of the University of 
Pennsylvania. In brief, tadpoles were incubated for 30 min in 
Petri dishes (10 tadpoles per dish) with varying concentrations 
of 4-fluoropropofol or propofol dissolved in pond water, con-
taining <0.01% DMSO as vehicle. Hypnosis, or immobility, was 
determined by the percentage of tadpoles that did not demon-
strate spontaneous movement in a 30-s evaluation period at the 
end of the 30-min incubation. After the anesthetic exposures, 
the tadpoles were transferred to fresh pond water and observed 
overnight for signs of toxicity. The water temperature was main-
tained at 21–22°C throughout the experiments. Values are repre-
sented as the mean ± SEM for three replicates. Data were fit to the 
following sigmoidal dose response curve with variable Hill slope:
  Y = bottom +  top − bottom  ________________  
1 + 1  0 (logE C 50 −X)×HillSlope 
, (4)
where X is the logarithm of the concentrations of propofol or 
4-fluoropropofol.
Online supplemental material
Fig. S1 shows changes in NaChBac activation and inactivation gat-
ing parameters induced by 4-fluoropropofol. Table S1 shows the 
predicted propofol binding sites identified by molecular docking 
on template NaV channel crystal structures. Fig. S2 shows the ef-
fects of single-cysteine mutations on the function of NaChBac. 
Fig. S3 shows the effects of 4-fluoropropofol on NaChBac mu-
tant gating and kinetics. Fig. S4 shows stack plots of 19F STD NMR 
spectra between 4-fluoropropofol and NaChBac.
Results
4-Fluoropropofol as a surrogate for propofol
Because propofol does not naturally contain any fluorine atoms, 
a fluorinated analogue was needed to measure the strength of 
propofol interactions with 19F STD NMR. We synthesized 4-flu-
oropropofol following a procedure described in the literature 
(Yuan et al., 2017) and determined the anesthetizing concen-
trations of propofol and 4-fluoropropofol in vivo by assessing 
immobility in tadpoles. The percentage of immobilized tadpoles 
from three separate trials with 10 tadpoles per drug per trial is 
plotted in Fig. 1 as a function of drug concentration for propo-
fol or 4-fluoropropofol. The EC50 values, determined from the 
nonlinear fitting to the dose–response curves (Eq. 2), are given 
as mean (95% confidence interval): propofol, 0.89 (0.82–0.96) 
µM and 4-fluoropropofol, 0.84 (0.73–0.97) µM. Hill slopes are 
3.21 ± 0.36 and 2.73 ± 0.49 for propofol and 4-fluoropropofol, re-
spectively. The two-tailed Student’s t test shows no significant 
difference between the anesthetizing potencies of propofol and 
4-fluoropropofol.
In addition to the in vivo effects, we also evaluated the in vitro 
functional relevance of using 4-fluoropropofol to probe propo-
fol action through electrophysiological measurements of NaCh-
Bac modulation by 4-fluoropropofol. Fig. 2 summarizes paired 
electrophysiology measurements in the absence and presence of 
4-fluoropropofol. Like propofol, 4 µM 4-fluoropropofol signifi-
cantly reduced the time constant of inactivation (Fig. 2, A–C) and 
induced parallel hyperpolarizing shifts of both the G-V (Fig. 2 D, 
left) and prepulse inactivation curves (Fig. 2 E, left). These shifts 
corresponded to changes in the midpoint (ΔV1/2) of activation and 
inactivation of −14.11 ± 1.87 mV and −10.96 ± 0.80 mV, respec-
tively, closely matching the experimental values for propofol as 
detailed in the companion paper (Yang et al., 2018a).
To evaluate lower affinity interactions, we also examined the 
functional effects of 4-fluoropropofol at a 10-fold higher (but still 
clinically relevant) concentration (Khan et al., 2014). At 40 µM, 
4-fluoropropofol induced a dramatic acceleration of the current 
decay (Fig. 2, B and C) and inhibited the peak current by 55% as 
determined by the average of the paired ratios (Fig. S1 A). This 
concentration of 4-fluoropropofol also changed the slope of the 
activation curve, giving some indication of hyperpolarization, 
but the V1/2 of activation did not change significantly (Fig. 2 D, 
right; and Fig. S1 A). It also strongly hyperpolarized the prepulse 
inactivation curve, corresponding to a ΔV1/2 of inactivation of 
–49.87 ± 5.95 mV, and reduced the associated effective gating 
charge (Fig. 2 E, right; and Fig. S1 B). At higher concentrations, 
4-fluoropropofol might inhibit NaChBac by pore blockade and 
stabilization of the inactivated state, in addition to the gating ac-
celeration effects as seen at lower concentrations (see Discussion). 
The combined results of the in vitro and in vivo measurements 
validate the physiological relevance of using 4-fluoropropofol as 
a fluorinated surrogate of propofol in binding analyses.
Multiple predicted propofol binding sites in NaChBac
As a general anesthetic with relatively low affinity for its protein 
targets, propofol likely binds to multiple distinct sites in NaChBac 
Figure 1. In vivo anesthetizing concentrations of propofol and 4-flu-
oropropofol in albino X. laevis tadpoles are identical. The percentage of 
immobilized tadpoles is plotted as a function of propofol and 4-fluoropropofol 
concentrations. The solid lines are best fit to the data by using Eq. 4. Error bars 
show the SEMs from three independent measurements with 10 tadpoles per 
measurement at each drug concentration.
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to produce its net inhibitory effects. To broadly examine all po-
tential propofol-binding sites, we used two complementary com-
putational techniques, molecular docking and MD simulations, 
as a preliminary screen to guide further experimental quanti-
fication. In the molecular docking calculations, both propofol 
and 4-fluoropropofol were screened on five structural models of 
NaChBac in a variety of putative functional states. Four distinct 
binding sites were observed with occupancies ≥10% for either 
propofol or 4-fluoropropofol (Fig. 3 A and Table 1). Both com-
pounds bound to each of these four sites with similar occupan-
Figure 2. 4-Fluoropropofol modulates voltage-dependent activation and inactivation of NaChBac. (A) Representative paired current families in the 
absence (control) and presence of 4 µM 4-fluoropropofol. (B) Paired currents at +20 mV. The 4-µM 4-fluoropropofol trace is shown scaled to its respective 
control Ipeak. The 40-µM 4-fluoropropofol trace is shown both as a raw current and scaled to its respective control Ipeak. (C) Time constants of inactivation (τ) 
versus voltage of control (n = 20) and 4-fluoropropofol at 4 and 40 µM (n = 8–12). 4-Fluoropropofol reduced τInactivation at both concentrations and all voltages 
(P < 0.0001, paired t test). (D and E) Normalized G-V (D) and prepulse (E) inactivation curves of control and 4-fluoropropofol at the indicated concentrations 
(n = 5–12). Corresponding midpoints (V1/2) of activation and inactivation are shown below the corresponding curves. Means are indicated in magenta. Data are 
reported as mean ± SEM from n independent measurements.
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cies and energies, analogous to the in vitro and in vivo functional 
results above, indicating there are no significant differences in 
propofol and 4-fluoropropofol binding to NaChBac. In addition, 
docking propofol and 4-fluoropropofol to the original (exper-
imental) template crystal structures of NaV channels used to 
construct the five NaChBac models did not reveal any additional 
binding sites (Table S1).
Docking results from four of the five NaChBac structures 
showed the highest propofol/4-fluoropropofol occupancy at the 
same binding site within the selectivity filter inside the pore 
(Fig.  3  B). One other potential binding site, inside the central 
pore cavity directly above the activation gate, was also observed 
in two of the five NaChBac structures but with lower occupancy 
than the selectivity filter site (Fig. 3 C). The combined docking 
results show a high likelihood for propofol binding at these two 
sites and consequently both were considered in subsequent 19F 
STD NMR experiments. The other two potential binding sites 
(the apex of the VSD and an intersubunit site at the extracellular 
interface of the PD) were observed in the docking results from 
only one of the five screened NaChBac structures (Table 1); be-
cause these docking calculations provide only a rough estimate 
of potential propofol binding sites, an additional MD simula-
tion of NaChBac conducted with an excess of propofol was per-
formed to further clarify which sites have the highest potential 
for propofol binding.
Within the first 150 ns of the flooding simulation, nearly all 
propofol molecules partitioned into the lipid bilayer membrane 
and accumulated near the transmembrane surface of NaChBac. 
A propofol density map averaged over the course of the following 
1-µs simulation revealed two binding sites with >90% occupancy, 
i.e., sites where propofol was persistently bound after the initial 
equilibration (Fig. 3 D). The first is a site in the apex of the VSD 
at the N-terminal end of the S4 helix, matching that observed 
previously in molecular docking on one of the screened NaCh-
Bac structures (Fig. 3 E). The second is an intersubunit site at the 
intracellular interface between the S4–S5 linker helix of one sub-
unit and the S5 and S6 helices of another subunit (Fig. 3 F). With 
such a high occupancy throughout the simulation providing 
Figure 3. In silico predicted propofol binding sites in NaChBac. (A) Top and side views of a NaChBac structure model with putative propofol binding sites 
identified by molecular docking (cyan spheres, occupancy ≥ 10%). (B and C) Zoomed-in views of the lowest energy conformation from docking calculations 
of propofol (cyan) bound to NaChBac inside the pore at the selectivity filter (B) and above the activation gate (C). Residues in close proximity to the docked 
propofol are shown as sticks labeled with the corresponding color. Note that residues selected for 19F labeling in STD NMR experiments (T189, I223, F227) are 
within the binding sites but unlikely to be essential for propofol binding to these regions. (D) Top and side views of NaChBac from the final frame of the 1-µs 
flooding MD simulation with putative propofol-binding sites (cyan spheres, occupancy ≥ 90%). (E and F) Zoomed-in views of propofol bound to NaChBac in the 
final frame of the 1-µs flooding MD simulation in the apex of the voltage-sensing domain (E) and an intersubunit site at the intracellular interface (F). Residues 
in close proximity to the docked propofol are shown as sticks labeled with the corresponding color. Note that residues selected for 19F labeling in STD NMR 
experiments (N36, V40, S129, L150) are within the binding sites but unlikely to be essential for propofol binding to these regions.
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strong in silico evidence of propofol binding, these two potential 
sites were also considered in subsequent 19F STD NMR experi-
ments. In total, computational screening implicated four binding 
sites for favorable propofol binding: the selectivity filter, the acti-
vation gate in the pore, the apex of the VSD, and the S4–S5 linker.
An intrasubunit binding site at the extracellular interface of 
the PD, which was confirmed to bind the volatile anesthetic iso-
flurane (Kinde et al., 2016), was not predicted to bind propofol 
by either computational approach. This intrasubunit site (S208) 
was also included in the following 19F STD NMR experiments as a 
measure of nonspecific propofol binding, i.e., to serve as a nega-
tive control for residual 19F magnetization transfer.
Mutational analysis of putative 4-fluoropropofol binding sites
Residue-specific binding analyses with 19F STD NMR require 
cysteine residues for selective 19F labeling. Cysteine mutations 
are typically well tolerated in membrane proteins; however, any 
mutation has the potential to disrupt drug binding. Molecular 
details of the putative propofol binding sites predicted by the 
computational calculations described above were used to identify 
residues within the binding sites that were unlikely to be criti-
cal for propofol binding (T189, F227, V40, and S129; Fig. 3). We 
then investigated the effects of the introduced cysteines at each 
potential binding site on NaChBac channel function and 4-fluo-
ropropofol inhibition. Fig. 4 A compares the voltage dependence 
of activation and inactivation for WT and the four NaChBac mu-
tants. The gating parameters are summarized in Table 2. All four 
mutants exhibited baseline V1/2 values of activation that were not 
statistically different from that of the WT (one-way ANO VA with 
Bonferroni post hoc correction), and only S129C demonstrated 
changes in the effective gating charge of activation. At baseline, 
S129C and F227C had prepulse inactivation curves that were 
hyperpolarized compared with the WT, whereas that of V40C 
was depolarized compared with the WT (Table 2). Cysteine mu-
tations at S129 and F227 reduced the effective gating charge of 
inactivation and accelerated the rate of current decay (Fig. S2). 
However, the mutations overall were well tolerated, with some 
changes seen with mutations at locations critical for gating (e.g. 
the S4–S5 linker and activation gate).
The effects of 4 µM 4-fluoropropofol on the voltage depen-
dence of activation and inactivation of each mutant compared 
with the WT are depicted in Fig.  4, B–D, and summarized in 
Table  3. In all mutants except F227C, 4  µM 4-fluoropropofol 
induced hyperpolarizing shifts in the V1/2 values of activation 
compared with the respective control without 4-fluoropropofol 
(Fig. S3), and the ΔV1/2 of these shifts was not significantly dif-
ferent between the WT and all four mutants (one-way ANO VA 
with Bonferroni post hoc correction; Fig. 4 B). In addition, in all 
mutants except S129C, the presence of 4  µM 4-fluoropropofol 
also produced hyperpolarizing shifts in the V1/2 values of in-
activation compared with the respective control (Fig. S3), and 
the ΔV1/2 of these shifts was not significantly different between 
WT and all mutants except S129C (one-way ANO VA, Bonferroni 
post hoc correction). The mutant S129C showed a significantly 
smaller ΔV1/2 of inactivation by 4 µM 4-fluoropropofol than the 
WT (Fig. 4 C), but this is likely because the S129C mutation al-
ready strongly hyperpolarized the prepulse inactivation curve 
under basal conditions (Fig. S2). Similar to what we observed 
for propofol (Yang et al., 2018a), 4-fluoropropofol accelerated 
the rate of current decay (Fig. S3) and in all four mutants, the 
Table 1. Potential propofol binding sites in NaChBac identified by molecular docking
Binding site NaChBac template structure (PDB) Compounda Occupancy Lowest energy score
% kcal/mol
Selectivity filter NavAb (3RVY) PFL 51.2 −6.20
4FPFL 70.2 −6.19
NavAb (5VB2) PFL 99.6 −6.76
4FPFL 90.6 −6.53
NavAb (5VB8) PFL 98.4 −6.71
4FPFL 81.6 −6.58
NavMs (5HVX) PFL 100.0 −6.92
4FPFL 98.2 −6.64
Activation gate NavAb (5VB8) PFL 1.6 −6.56
4FPFL 17.6 −6.44
NavRh (4DXW) PFL 19.7 −6.52
4FPFL 33.8 −6.50
Voltage sensing domain NavAb (3RVY) PFL 39.6 −6.61
4FPFL 24.0 −6.72
Intersubunit extracellular interface NavRh (4DXW) PFL 63.5 −6.49
4FPFL 52.5 −6.53
aPFL, propofol; 4FPFL, 4-fluoropropofol.
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Figure 4. Effects of single-cysteine mutations on NaChBac modulation by 4-fluoropropofol. (A) Paired G-V and prepulse inactivation curves without 
(black) and with (light blue) 4 µM 4-fluoropropofol (n = 4–13) for WT and each NaChBac mutant. (B and C) ΔV1/2 values of activation (B) and inactivation (C) 
induced by 4 µM 4-fluoropropofol for WT and NaChBac mutants. The ΔV1/2 values of activation were not significantly different between WT and the mutants. Of 
the four mutants, only S129C shows significantly different ΔV1/2 of inactivation from the WT (P = 0.0384, one-way ANO VA with Bonferroni post hoc correction). 
(D) Fold-change in time constants (τ) of inactivation (τ4-fluoropropofol/τcontrol) at +20 mV induced by 4 µM 4-fluoropropofol. Time constants were derived from 
the decaying phase of the Na+ currents, which were well described by the single exponential function. For all mutants, the fold-change in τInactivation caused 
by 4 µM 4-fluoropropofol was not significantly different from that of WT (one-way ANO VA with Bonferroni post hoc correction). Data are reported as mean ± 
SEM from n independent measurements.
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fold-change in the time constants of inactivation induced by 
4 µM 4-fluoropropofol at +20 mV was not significantly different 
from that in the WT (Fig. 4 D). These results provide additional 
evidence that the selected cysteine mutations did not hamper 
voltage-dependent gating or the functional responses to 4-flu-
oropropofol, which were generally similar to those for propofol 
(Yang et al., 2018a).
Residue-specific interactions quantified by 19F STD 
NMR measurements
For each of the four potential propofol binding sites identified by 
computational screening (T189, F227, V40, and S129) as well as 
the negative control binding site at the extracellular interface of 
the PD (S208), single-cysteine NaChBac mutants were prepared 
and covalently linked to a BTFA probe to produce residue-specific 
19F protein resonance. Additional NaChBac mutants were simi-
larly prepared for three of the putative binding sites for further 
confirmation of propofol interactions at the specific sites (I223C, 
N36C, and L150C). Mutations to other residues in the predicted 
binding site at the selectivity filter were likely to disrupt propo-
fol binding and/or native channel function, so only T189C was 
considered at that site. The distance limit of detection for 19F STD 
NMR is <10 Å (Jayalakshmi and Rama Krishna, 2002, 2004); the 
five regions of NaChBac examined by NMR are separated from 
each other by at least 15 Å. Hence, the observed STD signal is pro-
duced by 4-fluoropropofol binding close to the 19F-labeled resi-
due and does not include any long-range effects from binding to 
another region of NaChBac. The 19F-labeling efficiency for most 
mutants was 20–50%, except for N36C and F227C, which had 
∼10% 19F labeling efficiency. Because 19F-NMR background signal 
is nonexistent in proteins, the relatively low labeling efficiency is 
sufficient for STD measurements. In addition, we confirmed that 
unlabeled NaChBac produced STD signals for 4-fluoropropofol 
that were indistinguishable from noise, i.e., the on- and off-res-
onance spectra had equal intensities (equal Ion and Ioff in Eq. 2) at 
the 4-fluoropropofol peak position, leading to complete cancel-
lation of STD signals. This suggests that (a) unlabeled NaChBac 
(NMR invisible) does not interfere with the STD results, and (b) 
any imperfections in NMR hardware were below the detection 
limit. Note that the functional analysis of cysteine mutations de-
scribed above was performed for unlabeled NaChBac mutants. 
Although labeling with BTFA probe might influence the function 
of the NaChBac mutants, this effect would be exceedingly diffi-
cult to observe: labeling efficiency in live cells is expected to be 
even lower than that achieved for NMR samples. Unlike 19F-NMR 
experiments in which only the labeled proteins contribute to the 
STD signals, the majority of the response in electrophysiology 
experiments would be mostly from unlabeled protein because 
Table 2. Baseline gating parameters of NaChBac single-cysteine mutants
NaChBac mutant Activation Inactivation
V1/2 Z V1/2 Z
mV e0 mV e0
WT −33.93 ± 1.26 3.34 ± 0.19 −54.08 ± 0.53 6.73 ± 0.28
V40C −28.15 ± 1.62 3.29 ± 0.38 −47.34 ± 1.96*** 6.19 ± 0.32
S129C −41.68 ± 2.64 1.66 ± 0.17* −77.84 ± 0.65*** 3.66 ± 0.33*
T189C −40.48 ± 1.09 4.23 ± 0.82 −58.04 ± 1.22 7.01 ± 0.33
F227C −32.56 ± 4.36 2.18 ± 0.21 −60.84 ± 1.73** 5.07 ± 0.57*
Values are given as mean ± SEM (n = 4–12). Gating parameters of NaChBac WT versus each mutant, evaluated by one-way ANO VA with Bonferroni post 
hoc correction: *, P < 0.05; **, P < 0.01; ***, P < 0.0001. 
Table 3. Changes in NaChBac gating parameters induced by 4 µM 4-fluoropropofol
NaChBac mutant Activation Inactivation
ΔV1/2 ΔZ ΔV1/2 ΔZ
mV e0 mV e0
WT −14.11 ± 1.87§§§ 0.24 ± 0.32 −10.96 ± 0.80§§§ −0.78 ± 0.21
V40C −14.33 ± 1.20§§§ 0.29 ± 0.35 −10.56 ± 1.51§§ −0.28 ± 0.32
S129C −6.76 ± 2.37§ −0.17 ± 0.08 −3.73 ± 3.49* 0.20 ± 0.81
T189C −15.77 ± 1.92§§ 0.80 ± 0.14§ −8.61 ± 2.02§ −0.78 ± 0.26
F227C −6.58 ± 3.11 −0.26 ± 0.18 −17.30 ± 1.29§§§ −4.80 ± 0.58§§,***
Values are given as mean ± SEM (n = 4–13). Control versus 4-fluoropropofol for each mutant, evaluated by paired t test: §, P < 0.05; §§, P < 0.01; §§§, P < 
0.001. Change induced by 4-fluoropropofol in NaChBac WT versus in each mutant, evaluated by one-way ANO VA with Bonferroni post hoc correction: *, P 
< 0.05; ***, P < 1E-4.
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of low labeling efficiency, essentially nullifying any attempts to 
chemically label live cells for functional measurements.
Fig.  5  A depicts representative 19F-NMR spectra showing 
well-separated protein and 4-fluoropropofol peaks around −83.8 
ppm and −121.7 ppm, respectively. Fig. 5 B is a stack plot of STD 
spectra showing an example of strong intermolecular saturation 
transfers between 4-fluoropropofol and a BTFA probe placed at 
S129C in the S4–S5 linker. Additional 19F-NMR spectra for the 
other tested NaChBac mutants are shown in the online supple-
mental materials (Fig. S4). In contrast to S129C, saturation of the 
BTFA resonance linked to S208C produces very weak saturation 
transfer to 4-fluoropropofol (Fig. 5 C). Fig. 6 summarizes the STD 
accumulations as a function of saturation time for various mu-
tants grouped by binding site. The solid lines are best fit to the 
data by using Eq. 1. The cross-relaxation rate constants from the 
fitting are summarized in Table 4. As expected, 4-fluoropropofol 
does not bind measurably to the intrasubunit site at the extra-
cellular interfacial region (Fig. 6 A): although the maximum STD 
accumulation from S208C to 4-fluoropropofol is nonzero (3%), 
the curve–fit saturation time constant (ksat) is not different from 
zero based on the Student’s t test at the 95% significance level. In 
contrast, 4-fluoropropofol shows significant resonance transfer 
to residues in all four predicted binding sites (Fig. 6, B–D). The 
largest cross relaxation occurs between 4-fluoropropofol and 
F227C in the activation gate at the cytoplasmic entrance to the 
pore region. The next strongest 4-fluoropropofol cross relax-
ation is observed in the pocket at apex of the VSD, right above 
the hydrophobic constriction site at the crossing of the S4 and S1 
helices (N36C, V40C). Another binding site bordered by S129C 
at the beginning of the S4–S5 linker and L150C in the S5 helix of 
the adjacent subunit also showed strong STD build-up to 4-flu-
oropropofol. Finally, the end of the selectivity filter (T189C) and 
the central cavity of the pore (I223C) also show sizable saturation 
transfer from the protein resonance to the 4-fluoropropofol reso-
nance, suggesting that a significant amount of 4-fluoropropofol 
is likely trapped inside the pore.
Discussion
In this study, we combined computational prediction and site-di-
rected intermolecular 19F-NMR STD measurements to identify 
specific propofol-binding sites in NaChBac. At least four distinct 
sites have been identified by their STD cross-relaxation rates. We 
do not exclude the possibility that other propofol-binding sites in 
NaChBac may exist that were not examined in this study, includ-
ing the site at the intersubunit extracellular interface (Table 1). 
The same intersubunit site was found in a propofol-flooding MD 
simulation on NavMs (Yang et al., 2018a). As mentioned in the 
introduction, the rate of saturation transfer depends on several 
factors, including dynamics of the protein and ligand, residence 
time of the ligand in the binding site, and orientation of the 19F 
probes on the protein and ligand (Streiff et al., 2004; Angulo et 
al., 2010; Venkitakrishnan et al., 2012). As such, the cross-relax-
ation rate constant is a direct measure of the net magnetization 
transfer and hence the binding affinity between the 19F labels on 
NaChBac and 4-fluoropropofol. It should be noted, however, that 
the σ values cannot be directly interpreted in terms of apparent 
Kd without additional measurements at other ligand concentra-
tions. It should also be noted that the 4-fluoropropofol concentra-
tion used in the NMR experiments (200 µM) is higher than those 
used in the electrophysiology measurements (4 and 40 µM) be-
cause of the low NMR detection sensitivity. However, the clinical 
propofol concentration required to produce loss of consciousness 
in humans can be as high as 160 µM in the plasma (Khan et al., 
2014), and the plasma concentration is typically only 1–3% of the 
total propofol partitioned in the lipophilic compartment of the 
blood and brain tissue (Sall et al., 2012).
Figure 5. 19F-NMR measurements of 4-fluoropropofol binding to NaCh-
Bac. (A) Representative 19F-NMR spectra of the BTFA-labeled S129C NaChBac 
mutant in the presence of 200 µM 4-fluoropropofol with selective on- (black, 
Ion) and off-resonance (red, Ioff) saturation of the BTFA peak. The saturation 
time was 2 s. (B) Stack plot of 19F STD NMR spectra showing that 4-fluoro-
propofol interacts specifically with the BTFA labeled at S129C for intermolec-
ular saturation transfer to be built up at longer saturation time (τ). (C) Stack 
plot of 19F STD NMR spectra showing that 4-fluoropropofol has no measurable 
interaction with the negative control BTFA-labeled S208C NaChBac.
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The four propofol-binding sites identified in this study can 
be grouped into three separate regions. The first is in the PD 
within the ion-conducting passage, where propofol is found to 
interact with residues at the base of the selectivity filter (T189), 
inside the central cavity (I223), and at the activation gate (F227). 
The other two regions are in the apex of the VSD (N36, V40) and 
between the S4–S5 linker and the S5 or S6 helix from an adja-
cent subunit (S129, L150). At clinically relevant concentrations, 
one or more of these binding sites can potentially be occupied. 
Site-directed 19F-NMR measurements strongly support the no-
tion that multiple sites are involved in the allosteric modulation 
of NaChBac by propofol. It is also possible that occupancy of these 
sites is state dependent because all identified sites are associated 
with regions known to change conformation during activation 
and/or inactivation of voltage-gated ion channels. In particular, 
the aqueous cleft above the hydrophobic constriction site in the 
VSD and the interhelical packing between the S4–S5 linker and 
its interfacing S5 and S6 helices from the adjacent subunits are 
critical for electromechanical coupling. However, because NMR 
measurements were necessarily performed at depolarized (zero) 
cross-membrane potential, additional experiments are required 
to explore this possibility.
The fluorinated propofol partitioned into the channel pore 
and showed intermolecular 19F saturation transfer with T189, 
the residue that marks the border between the narrow selec-
tivity filter and the broad central aqueous cavity. An interpre-
tation of this result is that the strong and specific interaction 
between 4-fluoropropofol and T189 causes drug-induced con-
formational changes in the selectivity filter (Pavlov et al., 
2005), leading to an accelerated inactivation. An alternative 
interpretation supports the notion that high concentrations of 
propofol may partition into the pore to directly influence Na+ 
conductance. However, electrophysiology data detailed in the 
companion paper (Yang et al., 2018a) suggest that propofol at 
low concentrations does not block the pore of NaChBac. There-
fore, it is possible that the central cavity weakly binds propofol 
at all pore-lining residues from T189 down to F227. Supporting 
this possibility, our results with 40 µM 4-fluoropropofol (Figs. 
2 and S1) showed that the predominant action of propofol at 
high concentrations involved pore blockade via weak interac-
tions, as indicated by the truncation of the peak current and 
dramatically accelerated current decay, suggesting the possible 
involvement of blocking kinetics. The accelerated current decay 
confounds the hyperpolarizing shift in the G-V curve otherwise 
Figure 6. Quantitative analysis of 19F NMR STD build-up from individ-
ual mutation sites in NaChBac to 4-fluoropropofol. Mutations are grouped 
by four regions: (A) the extracellular interface (S208), (B) the S4–S5 linker 
region (L150C, S129C), (C) the apex of the voltage sensing domain (N36C, 
V40C), and (D) the pore region (F227C, I223, T189C). The solid lines are the 
best fit to the data by using the two-parameter equation (Eq. 1), yielding the 
cross-relaxation rate constant and the saturating magnetization transfer from 
the 19F labels on NaChBac to 4-fluoropropofol. Error bars are uncertainties 
calculated from the root-mean-squared noise-to-signal ratios in the on- and 
off-resonance 19F NMR spectra.
Table 4. Summary of 4-fluoropropofol binding at various sites in NaChBac
Region Residue STDmax ksat σ × 100
% s–1 s−1
Intrasubunit extracellular interface S208 3.0 ± 1.0* 0.7 ± 0.5 2.1 ± 1.7
Voltage sensing domain N36 11.4 ± 0.5*** 2.0 ± 0.3** 22.3 ± 3.7**
V40 9.1 ± 0.5*** 2.8 ± 0.6** 25.5 ± 5.5**
S4–S5 linker S129 8.4 ± 0.3*** 1.9 ± 0.3** 15.8 ± 2.7**
L150 9.5 ± 0.6*** 1.6 ± 0.3** 15.5 ± 3.1**
Selectivity filter T189 9.0 ± 0.5*** 2.2 ± 0.4** 19.7 ± 3.8**
Activation gate F227 17.4 ± 0.9*** 2.5 ± 0.4** 42.6 ± 7.6**
I223 9.7 ± 0.5*** 1.4 ± 0.2** 13.3 ± 2.3**
I223a 10.0 ± 0.4† 1.7 ± 0.2† 17.4 ± 1.5††
I223b 8.0 ± 0.5† 1.1 ± 0.2† 8.4 ± 1.2††
Values are given as mean ± SEM. Difference from zero was evaluated individually for each parameter by the Student’s t test: *, P < 0.05; **, P < 0.01; ***, P 
< 0.001. Difference between parameters obtained in the absence and presence of etidocaine was evaluated by the Student’s t test: †, P < 0.05; ††, P < 0.01.
aMeasured by using 100 µM 4-fluoropropofol without the local anesthetic etidocaine.
bMeasured by using 100 µM 4-fluoropropofol in competition with 50 µM etidocaine.
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observed at low propofol and 4-fluoropropofol concentrations. 
At 40 µM, 4-fluoropropofol also induced a dramatic hyperpo-
larizing shift of the prepulse inactivation curve, which addi-
tionally appeared shallower, suggesting a slower recovery from 
inactivation because of pore blockade-induced stabilization of 
the inactivated state.
The site with the largest cross-relaxation rate constant iden-
tified in the current study is located at the activation gate (F227; 
Fig. 6). As discussed above, the predominant action of propofol 
at high concentrations is to accelerate inactivation. This accel-
eration can be attributed, at least partially, to propofol binding 
near the activation gate at F227, especially considering the elec-
trophysiology evidence that the F227C mutation by itself acceler-
ates the rate of current decay and moves the V1/2 of inactivation 
significantly in the hyperpolarization direction relative to that 
of the WT NaChBac (Table 2 and Fig. S2). Although the F227C 
mutation alone did induce a significant shift in the ΔZinactivation 
by 4-fluoropropofol compared with WT NaChBac (Table 3), the 
strong cross relaxation between fluorine probes at F227 and 
4-fluoropropofol suggests that, at the concentration used in 
NMR studies, 4-fluoropropofol accumulates inside the pore of 
NaChBac. It is conceivable that occupying the site near F227 by 
amphipathic drugs like propofol may sensitively promote chan-
nel inactivation.
A similar mechanism of action has been proposed for local 
anesthetics that block the NaV channel pore and stabilize the 
inactivated state (Goldschen-Ohm and Chanda, 2014): muta-
genesis experiments have implicated NaV1.2 residues F1764 
and Y1771 (equivalent to NaChBac residues T220 and F227, 
respectively [Boiteux et al., 2014]) in local anesthetic binding 
(Ragsdale et al., 1994). To further investigate whether local an-
esthetics and propofol have an intersecting site of action in the 
pore of NaChBac, we measured the STD signal from I223C to 
4-fluoropropofol in the absence and presence of 50 µM etido-
caine (Fig. 7). In general, STD NMR experiments are intrinsi-
cally insensitive to silent competition partners because the STD 
signal is the result of an accumulation of magnetization satu-
ration transfer from the protein to the ligand in fast exchange 
over a relatively long acquisition period. However, at a lower 
concentration of 4-fluoropropofol (100  µM), the relatively 
tight binding of etidocaine (Kd ∼1 µM for the inactivated state 
of NaV1.2 [Ragsdale et al., 1994]) allowed us to observe a signif-
icant decrease in the cross-relaxation rate of 4-fluoropropofol 
binding in the pore of NaChBac (Table 4). Thus, although the 
mechanisms may differ, local anesthetics and propofol seem 
to share an overlapping site of action. Additional 19F STD NMR 
experiments with a fluorinated local anesthetic analogue or 
electrophysiological competition experiments could be used to 
further support this prediction.
Binding to the apex of the VSD has not been reported before 
for any general anesthetic but is supported here by direct ex-
perimental measures of intermolecular 19F saturation transfer. 
Anesthetic binding at this site likely modulates gating charge 
movement. A previous study suggested that the sliding of gat-
ing charges across a hydrophobic “girdle” depends on favor-
able electrostatic interactions of the gating charges against the 
complementary surfaces that consist of an extracellular neg-
ative-charge cluster and intracellular negative-charge cluster 
(Payandeh et al., 2011). The major energy barrier comes from 
moving the gating charges in the S4 helix to pass a focused 
electric field at the hydrophobic constriction site. It is conceiv-
able that amphipathic propofol or 4-fluoropropofol molecules 
located between the hydrophobic girdle and the hydrophilic 
water molecules in the aqueous cleft facilitate the sliding 
movement of S4, favoring a transition to the open state. This 
is consistent with the parallel leftward shift of the G-V curve 
observed in this study with 4-fluoropropofol and in our other 
studies with propofol (Yang et al., 2018a). However, it is import-
Figure 7. Local anesthetic inhibition of 4-fluoropropofol 19F NMR STD 
signal in the pore of NaChBac. (A and B) Stack plots of 19F STD NMR spectra 
for 100 µM 4-fluoropropofol interacting with the BTFA labeled at I223C in the 
absence (A) and presence (B) of 50 µM etidocaine, a local anesthetic. (C) 19F 
NMR STD accumulation in the absence (black) and presence (red) of 50 µM 
etidocaine. The solid lines are the best fit to the data by using the two-pa-
rameter equation (Eq. 1), yielding the cross-relaxation rate constant and the 
saturating magnetization transfer from the 19F labels on I223C in NaChBac to 
4-fluoropropofol. Error bars are uncertainties calculated from the root-mean-
square noise-to-signal ratios in the on- and off-resonance 19F NMR spectra.
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ant to note that as the NMR measurements were performed at 
depolarized (zero) cross-membrane potential, it is also possible 
that the 4-fluoropropofol binding at the apex of VSD is state-de-
pendent and favors activated states (open and inactivated) over 
the resting states.
Like the volatile anesthetic isoflurane, 4-fluoropropofol inter-
acts specifically with the 19F labels placed at S129C and L150C, 
which in our structure model of NaChBac form a well-defined 
intersubunit pocket at the intracellular interface. However, the 
contributions of propofol binding at this site to channel function 
are complicated by the fact that the S129C mutation alone induced 
hyperpolarizing shifts in the voltage-dependence of activation 
and inactivation and accelerated the rate of channel inactivation 
(Table 2 and Fig. S2). Although our 19F STD measurements pro-
vide direct experimental evidence showing the involvement of 
the S4–S5 linker in propofol binding, how the binding at this site 
facilitates channel activation or accelerates slow inactivation, or 
both, requires further investigations. A possible scenario, based 
on the novel role of S4–S5 linker in the inactivation of eukary-
otic NaV subchannels, is proposed in the companion paper (Yang 
et al., 2018a).
Conclusion
Direct experimental evidence from this study supports the no-
tion that the intravenous general anesthetic propofol binds to 
multiple sites in the prokaryotic NaV channel NaChBac for al-
losteric modulation of gating. Propofol produces a net effect 
of inhibition to channel function by facilitating the activation 
process and potently promoting the slow inactivation process, 
shifting the channel population from the resting to the inacti-
vated states. Based on the locations of the propofol binding sites 
identified in this study, we hypothesize that propofol binding 
in the apex of VSD above the hydrophobic constriction site fa-
cilitates channel activation, whereas the binding in the channel 
pore, particularly at the activation gate near F227, accelerates 
channel inactivation. Propofol binding near the S4–S5 linker site 
might play a dual role by promoting opening and entry into an 
inactivated state. Additional experiments, however, are required 
to confirm these hypotheses.
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